Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pylera-based quadruple therapy versus omeprazole-amoxicillin-clarithromycin for Helicobacter pylori eradication
2007-006280-78Phase 3Completed
- Sponsor
- Axcan Pharma Inc.
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of bismuth subcitrate potassium + metronidazole + tetracycline hydrochloride, omeprazole, amoxicillin and clarithromycin in Helicobacter pylori infection (2 arms), sponsored by Axcan Pharma Inc. Primary endpoint: Helicobacter pylori eradication rate difference. Started Jan 2008; status: completed.
02
Drugs
bismuth subcitrate potassium + metronidazole + tetracycline hydrochlorideomeprazoleamoxicillinclarithromycin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on 2007-006280-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006280-78.